CEREBRAL lymphatic dysfunction is emerging as a promising therapeutic target in Alzheimer’s disease treatment and research.
Alzheimer’s disease remains difficult to treat effectively because conventional approaches have largely delivered modest symptomatic benefit without addressing the upstream processes that drive pathological protein accumulation. This review highlights the cerebral lymphatic system as a potentially disease modifying target, with growing evidence that impaired brain waste clearance contributes directly to amyloid β-protein deposition and cognitive decline.
Alzheimer’s Disease and Cerebral Lymphatic Therapy
The cerebral lymphatic system includes the glymphatic system within the brain parenchyma and meningeal lymphatic vessels in the dura. Together, these pathways help clear amyloid β-protein from the brain by supporting cerebrospinal fluid and interstitial fluid exchange, then draining solubilized waste toward deep cervical lymph nodes. The review describes this clearance network as a key mechanism in sporadic Alzheimer’s disease, where impaired removal of amyloid β-protein appears more relevant than overproduction.
Importantly, dysfunction in this system may occur before substantial plaque accumulation. Preclinical findings summarized in the review show that reduced lymphatic drainage is present even in younger disease models, supporting the concept that cerebral lymphatic impairment may be an upstream driver of pathology rather than a downstream consequence. Human data cited in the paper also point to abnormal protein deposition and biomarker accumulation along lymphatic drainage routes, reinforcing the clinical relevance of this pathway.
Emerging Therapeutic Strategies
The review outlines a wide range of therapeutic strategies designed to improve cerebral lymphatic function and enhance amyloid β-protein clearance. These include pharmacological approaches such as VEGF-C related signaling strategies, traditional Chinese medicine formulations, and oxytocin. Nonpharmacological approaches include near infrared photobiomodulation, 40 Hz light and sound stimulation, aerobic exercise, somatosensory stimulation, repetitive transcranial magnetic stimulation, and very low intensity ultrasound. Gene therapy and surgical approaches, including lymphatic venous anastomosis and cranial bone maneuver techniques, are also discussed.
Across these modalities, the therapeutic goal is consistent: restore drainage efficiency, improve lymphangiogenesis or vascular support, preserve aquaporin-4 polarity, and reduce the buildup of pathological proteins. While many of these strategies remain investigational and translational challenges persist, the review positions cerebral lymphatic therapy as an important shift in Alzheimer’s disease research, moving attention from symptom control toward clearance-based disease modification.
Reference
Mi F et al. Advancements in therapy for Alzheimer’s disease based on the cerebral lymphatic system. Degener Neurol Neuromuscul Dis. 2026;16:574901. doi:10.2147/DNND.S574901.
